Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) | Apply Online

Frequently Asked Questions (FAQs)

What is the funding opportunity?

This opportunity is the NIH National Cancer Institute (NCI) Funding Opportunity Announcement (FOA) RFA-CA-10-002 titled "Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33)." It supports later-stage technology development and validation focused on improving the quality and reliability of cancer biospecimens used in molecular research.

What problem is this FOA trying to solve?

The FOA targets pre-analytical variation: all factors that can affect a specimen before a molecular assay is performed. Examples include collection methods, time to processing, preservatives used, transport conditions, and storage duration/conditions. These variables can distort downstream molecular results and reduce comparability and reproducibility.

What types of biospecimens does the FOA focus on?

The focus is on cancer biospecimens and their derivatives. This can include primary specimens (such as tissue or blood) as well as derived analytes like extracted DNA, RNA, proteins, or other molecular components prepared from the original specimen.

What kinds of downstream molecular analyses are impacted by pre-analytical variation?

The FOA notes that pre-analytical factors can strongly affect genomic, proteomic, epigenomic, metabolomic, and other molecular readouts. The goal is to improve the accuracy and clinical or research meaning of these downstream analyses by improving specimen integrity and characterization.

What is the R33 mechanism intended to support in this program?

The R33 mechanism is intended for projects that have moved beyond early concept development. It is aimed at advanced development and validation, where proof of principle has already been demonstrated and supportive preliminary data can be provided.

Is this opportunity suitable for very early-stage or purely exploratory ideas?

No. The FOA is not meant to fund basic exploratory ideas without evidence they can work. It is positioned for technologies that already have proof of principle and now require advanced development and rigorous validation.

What kinds of projects are considered responsive?

The FOA seeks technically innovative projects focused on technologies and methodologies that improve biospecimen science by addressing pre-analytical variation. It supports the development and validation of tools, devices, instrumentation, and associated methods that assess quality, preserve integrity, and establish verification criteria for quality assessment/quality control under real-world conditions.

What are examples of technologies or methods the FOA intends to support?

Examples described in the FOA include: tools that assess sample quality; technologies that preserve or protect sample integrity; and approaches that create verification criteria for quality assessment, quality control, and handling across diverse conditions. The FOA also highlights possibilities like rapid sensors or assays that measure degradation, ischemia effects, contamination, or other integrity indicators, as well as improved stabilization chemistries or storage approaches.

Does the FOA require validation, not just invention?

Yes. A central emphasis is validation that builds confidence a technology will perform reliably across the types of variability commonly encountered in clinical and research workflows. The FOA stresses robustness across conditions and the establishment of credible quality assessment or quality control criteria.

What does "pre-analytical variation" mean in practical terms?

In practical terms, it includes how a specimen is collected, how long it sits before processing, which preservatives or stabilizers are used, how it is transported, and how it is stored over time. These steps can change the state of the specimen and affect molecular measurements later.

Is the FOA only about preserving specimens, or also about measuring quality?

It is about both. The FOA explicitly supports technologies that assess sample quality, preserve/protect sample integrity, and create verification criteria or decision rules to determine whether a specimen is fit for a given downstream molecular application.

What does it mean to create "verification criteria" for biospecimen quality?

It refers to developing standardized metrics, quality indicators, or decision rules that laboratories and biobanks can use to determine specimen integrity and fitness-for-purpose, including criteria relevant to handling and quality control across varying real-world conditions.

What kinds of projects are not responsive or may be considered out of scope?

Projects that mainly apply already-established technologies where the primary novelty is the biological or clinical question (rather than the technology itself) are considered out of scope and may be returned as non-responsive. The FOA is intended to fund advances in biospecimen science technologies and methodologies, not conventional studies that simply use existing platforms.

How does this R33 FOA relate to the NCI IMAT Program?

This FOA sits within the NCI Innovative Molecular Analysis Technologies (IMAT) Program, which aims to accelerate the development of novel technologies that improve molecular analysis in cancer research.

Is there a companion funding opportunity?

Yes. The FOA runs in parallel with a companion announcement of identical scientific scope using the R21 mechanism (RFA-CA-10-001). The R21 generally aligns with earlier, more exploratory development, while the R33 is for advanced development and validation after proof of principle.

Which agency is offering this grant?

The opportunity is offered by the National Institutes of Health (NIH) through the National Cancer Institute (NCI).

What is the total estimated funding amount for the program?

The estimated total funding amount listed is $2,250,000.

What is the award ceiling?

The award ceiling is $300,000.

Is cost sharing or matching required?

No. The opportunity indicates that there is no cost sharing or matching requirement.

What are the key dates for this FOA?

The posted date was October 26, 2009. The original and current closing date was September 30, 2010. The archive date was October 31, 2010.

What is the program type or administrative category?

It is a discretionary grant program within NIH. Activity categories are tied to education and health, with CFDA listings spanning cancer cause and prevention, detection and diagnosis, treatment, and biology research.

Who is eligible to apply?

Eligibility is broad and includes small businesses; for-profit organizations (including those other than small businesses); private and public institutions of higher education; nonprofits (with and without 501(c)(3) status, other than institutions of higher education); state governments; and other categories noted in the announcement.

Are federal agencies eligible?

The eligibility section indicates that federal agencies may be eligible, depending on the specific FOA terms.

Are non-U.S. (foreign) organizations eligible?

The eligibility section indicates that non-U.S. entities (foreign organizations) may be eligible, depending on the specific FOA terms.

Are U.S. territories or possessions eligible?

The eligibility section indicates that U.S. territories or possessions may be eligible, depending on the specific FOA terms.

What outcomes is NCI aiming for through this FOA?

The intended outcome is practical, validated technology that helps ensure biospecimens and derived analytes are high-quality, well-characterized, and fit for modern downstream molecular analyses, improving reliability and reproducibility across cancer research and translational studies.